noon on June 3. Dr. Lawrence Tamarkin, CEO of cytimmune will
present the poster abstract entitled "Prelimi...TNF
"Acceptance to ASCO provides cytimmune the opportunity to present
its research to the lea...ology
experts," said Dr. Lawrence Tamarkin, CEO of cytimmune Sciences.
"For an emerging company, it's a chance ...